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Abstract 
Background 
The 2006 National Heart Foundation and Cardiac Society of Australia and New Zealand 
(NHFA/CSANZ) guidelines on the management of acute coronary syndrome (ACS) 
recommended stratifying patients with possible ACS into low-, intermediate- and high-risk 
cohorts. Low- and intermediate-risk patients were assessed with serial cardiac biomarkers and 
electrocardiography (ECG). If negative results were obtained, further objective testing for 
intermediate-risk patients was required while low-risk patients may be discharged. High-risk 
patients required admission, which often included early invasive interventions as part of 
management. Biomarker testing was recommended on presentation (zero hours) and then six 
to eight hours later when using sensitive (contemporary) troponin assays. Such practice was 
resource-intensive and time-consuming.  
 
Local Problem 
The Emergency Department (ED) at the Royal Brisbane and Women’s Hospital (RBWH), a 
large tertiary hospital in Australia, had recently implemented the IMProved Assessment of 
Chest pain Trial (IMPACT) protocol, an accelerated diagnostic protocol for assessing patients 
presenting to the ED with possible ACS. The IMPACT protocol was evaluated in the IMPACT 
study, an intervention trial between February 2011 and March 2014. The IMPACT protocol 
was then immediately translated into clinical practice as the standard protocol for use at all 
hours (during and out of working hours) at the RBWH from April 2014. The IMPACT protocol 
utilised zero- and two-hour troponin testing for low- and intermediate-risk patients. Troponin 
ordering for high-risk patients was unchanged at zero and six hours.  
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This study sought to investigate whether the troponin ordering practices detailed by the 
IMPACT protocol were translated into clinical care in the post-implementation period.  
 
Methodology 
This was an observational study of adult patients presenting to the RBWH ED with chest pain 
between April 2014 and June 2016. The study included patients who had at least two troponins 
ordered, with the first being within four hours of presentation to the ED. Troponin data was 
obtained from the hospital pathology database. The proportion of patients in the overall cohort 
who had zero- and two-hour troponin testing was calculated along with median ED and short 
stay unit (SSU) length of stay, and proportion of patients admitted into hospital. 
 
Results 
The proportion of patients that had zero- and two-hour troponin testing, which was considered 
the accelerated cohort, increased rapidly over the first six months. The overall proportion of 
patients who underwent accelerated assessment during this study period was 49.2%. It reached 
a predicted 53.7% of the overall cohort by the end of this study, a figure less than that of the 
75.6% reported by the IMPACT study.  
 
The overall cohort was older than that recruited into the IMPACT study. After adjustment for 
age and sex (to the average age of the IMPACT cohort), the predicted proportion of accelerated 
patients was 66.7% for males and 72.7% for females by the end of the study period. The median 
ED and SSU length of stay was 7.2 hours for accelerated patients. The median hospital length 
of stay was 9.8 hours for accelerated patients and 23.9 hours for all patients. The proportion of 
patients admitted into hospital was 23.3% for accelerated patients, and 53.5% for the overall 
cohort.  
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Conclusions 
This study demonstrated that the IMPACT protocol was rapidly being adopted and utilised in 
a clinical setting following conclusion of the original trial. The initial increase in proportion of 
patients being accelerated, followed by a plateau before the end of the study period, indicated 
acceptability, adoption and sustainability of the IMPACT protocol. The secondary outcomes 
of ED and SSU length of stay and admission rates remained unchanged for accelerated patients 
across the post-implementation period, demonstrating sustainability and consistency in the use 
of the IMPACT protocol at the RBWH ED. 
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Introduction 
Each year in Australia, an estimated 500,000 patients present to hospital Emergency 
Departments (EDs) with possible cardiac chest pain.2 The most common serious aetiology of 
this symptom is acute coronary syndrome (ACS), which includes ST elevation myocardial 
infarction (STEMI), non-ST elevation myocardial infarction (NSTEMI) and unstable angina. 
In 2012, there were an estimated 68,200 acute coronary events in Australia.3 It is often difficult 
to distinguish an ACS from alternative aetiologies, including serious conditions such as 
pulmonary embolism and less life-threatening diagnoses such as gastro-oesophageal reflux. 
 
The assessment of chest pain in the ED focuses not only on the rapid diagnosis of ACS, but 
also on the exclusion of ACS and other serious conditions that may cause significant morbidity 
and mortality. Most patients undergoing investigations for ACS do not have the condition,4 but 
the serious consequences of a missed diagnosis encourage extensive investigations in patients 
with possible ACS. 
 
The diagnosis of ACS is based on history, clinical assessment, serial cardiac biomarker 
measurements, serial electrocardiography (ECG) and possibly cardiac imaging.5 The main 
biomarker used is cardiac troponin. Cardiac troponin is released in the event of myocardial cell 
damage and its degree of elevation correlates to the amount of myocardial cell death. Serial 
troponin testing is critical for the evaluation of ACS; troponin elevations are seen in multiple 
chronic cardiac and non-cardiac conditions, but a change in serial troponin levels is indicative 
of an acute cardiac injury and is an important component of acute myocardial infarction 
diagnosis.6,7 This underpins the importance of serial measurement of cardiac troponin. In 
addition, serum troponin levels are most commonly elevated six to eight hours after myocardial 
injury, with a peak at twelve to twenty-four hours, and remaining in circulation in the blood 
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for seven to ten days.8 If the initial troponin test was performed too close to the time of 
myocardial insult, the test may be reported as a normal result. Thus it is imperative for serial 
tests after an appropriate interval.7 
 
The 2006 National Heart Foundation and Cardiac Society of Australia and New Zealand 
(NHFA/CSANZ) guidelines9 on the management of ACS utilised serial troponin testing as part 
of stratifying patients into low-, intermediate- and high-risk categories.9,10 Serial troponin 
testing was recommended over a six to eight hour period when using sensitive (contemporary) 
troponin assays. The guidelines recommended that patients with low-risk clinical features, 
normal serial troponin and normal ECG results could be discharged from ED. Patients with 
intermediate-risk clinical features, normal serial troponin and normal ECG results were sent 
for further objective testing, the most commonly used being an exercise stress test (EST). Other 
more expensive investigations may include stress echocardiography, computed tomography 
coronary angiography, myocardial perfusion scanning and invasive coronary angiography. 
Patients with high-risk clinical features, elevated troponin or abnormal ECGs required 
admission to hospital and intensive management, often including early invasive strategies. 
Overall this process resulted in extended emergency stays and a high rate of admission, yet up 
to 67.2% of patients were ultimately diagnosed as having pain of non-cardiac origin and a 
further 20.8% were diagnosed with non-ACS cardiac conditions.4 Processes for the assessment 
of chest pain using the 2006 NHFA/CSANZ guidelines were expending valuable time and 
resources. Overcrowding and extended length of stay in EDs increased mortality.11,12 On the 
other hand, timeliness did not affect safety.13  
 
A recent intervention trial had shown that patients who were at low- or intermediate-risk of 
ACS could safely undergo an accelerated diagnostic protocol. The protocol, termed the 
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IMProved Assessment of Chest pain Trial (IMPACT) protocol (Figure 1),1 aimed to safely 
accelerate the assessment of low- and intermediate-risk patients. Firstly, the IMPACT protocol 
redefined low- and intermediate-risk characteristics (Supplementary Table 1), enabling a 
higher proportion of patients to be categorised as low risk. Secondly, it enabled serial troponin 
testing at zero and two hours for low- and intermediate-risk patients, rather than the zero and 
six hours recommended by traditional clinical guidelines. This allowed low-risk patients to be 
discharged earlier, and intermediate-risk patients to undergo objective testing earlier. The 
IMPACT trial was facilitated by research nurses during working hours, between 0800 and 1700 
hours on Monday to Friday between February 2011 and March 2014. The protocol was 
immediately translated into clinical practice, and became the standard protocol at all hours 
(during and out of working hours) at the Royal Brisbane and Women’s Hospital (RBWH) from 
April 2014. 
 
The IMPACT protocol was shown to be a safe and cost-effective strategy within the confines 
of a clinical trial; the average cost per patient managed by the IMPACT protocol was $1229 
less than the traditional NHFA/CSANZ approach, and saved twenty-six hours in hospital.1,14 
However, translation of research findings into guidelines is often difficult.15 As such, an 
evaluation of the usage of the IMPACT protocol was necessary. Further, an evaluation of its 
effectiveness in terms of secondary outcomes such as length of stay and admission rates was 
required.  
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Available knowledge 
The 2006 NHFA/CSANZ guidelines9 on the management of ACS recommended stratifying 
patients into low-, intermediate- and high-risk categories. Cullen et al.4 found that for patients 
presenting to an Australian ED with at least five minutes of chest pain suggestive of an ACS 
(acute chest, epigastric, neck, jaw, or arm pain; discomfort or pressure without an apparent 
non-cardiac source), the final cause of chest pain was a non-cardiac condition in 67.2% of 926 
patients. Non-ACS cardiovascular disease, including pericarditis and heart failure, was 
diagnosed in 20.8% of patients. ACS was diagnosed in 11.1% of patients, with the most 
common pathology being NSTEMI (51.5% of the ACS group).  
 
Using the 2006 NHFA/CSANZ guidelines, the total cost for assessing 580 intermediate-risk 
patients during this study was $1,916,100, and such assessment resulted in the identification of 
eleven ACS patients. This equated to $174,191 to identify and treat one ACS patient in the 
intermediate-risk group. In the high-risk group, the total cost of assessment was $2,934,317. 
Ninety-two patients out of 329 were diagnosed with ACS in the high-risk group, resulting in 
an average of $31,895 spent in identifying and treating one ACS event. Therefore, even though 
the high-risk group incurred the highest total cost, identifying the 1.9% of patients with ACS 
in the intermediate risk cohort was resource-intensive, with the costs expended to diagnose and 
treat a very small proportion.4 
 
Alongside high assessment costs, there had been evidence that the process of risk stratification 
for patients with ACS was often not strictly performed, with variation in test ordering and 
timing of tests. Resistance by emergency physicians to the use of the NHFA/CSANZ guidelines 
had been observed in some Australian hospitals.16 As such, a revised assessment approach for 
ED patients with chest pain that maintained safety while improving efficiency was warranted.  
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Accelerated chest pain protocols had been trialled and had facilitated early discharge both 
safely and effectively.17-19 An ideal accelerated diagnostic protocol would reduce unnecessary 
testing in patients who were low-risk for ACS and would streamline the overall assessment 
process for patients at intermediate-risk. This would save resources but with no adverse impact 
on health outcomes. Ideally, the protocol would also allow for a much shorter time frame for 
assessment of serial troponins. 
 
The IMPACT protocol is an alternative strategy to the 2006 NHFA/CSANZ protocol for 
assessing chest pain.1 The IMPACT protocol stratifies patients into low-, intermediate- and 
high-risk groups using demographic and clinical features (Figure 1). On presentation (zero 
hours), troponin testing and ECG are performed on all patients. For low- and intermediate-risk 
patients, this is repeated at two hours. Low-risk patients can be discharged upon normal results 
for troponin and ECG. Intermediate-risk patients with normal results in troponin and ECG 
undergo an inpatient EST. A negative EST allows the patient to be discharged; while positive 
or equivocal ESTs require patients to be referred to internal medicine or cardiology. High-risk 
patients receive serial troponin testing and ECG at zero and six hours, and are admitted as 
inpatients for further investigations and treatment.  
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Figure 1: IMPACT protocol (based on study by Cullen et al.1) 
 
 
A study by Cheng et al.14 found that using the 2006 NHFA/CSANZ guidelines,9 62% of 
patients were classed as intermediate-risk. 56% of this intermediate-risk cohort did not have an 
EST and were admitted to the ward for further investigations, incurring higher costs. In 
contrast, using the IMPACT protocol, 55% of patients were classed as intermediate-risk; 82% 
in this group had an EST and thus a smaller proportion of patients required admission for 
further, more expensive and potentially invasive investigations.14 Furthermore, the 2006 
NHFA/CSANZ guidelines classified <1% of patients presenting with chest pain into the low-
risk cohort, a category that was associated with lower costs due to less extensive investigations 
required. In comparison, the IMPACT protocol stratified 18% into the low-risk category. There 
was no increase in adverse events using the IMPACT protocol in comparison to the 
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NHFA/CSANZ protocol, and the IMPACT protocol allowed a higher proportion of low- and 
intermediate-risk patients to be discharged from ED within 4 hours (72% vs 51%).14 
 
Clinical Decision Rules (CDRs), such as the IMPACT protocol, are major applications of 
clinical research. They integrate clinical or laboratory results to provide a quantitative 
probability of a diagnosis or clinical outcome.20 The use of CDRs can improve the accuracy of 
risk stratification and usage of appropriate evidence-based therapies, and can decrease the 
number of unnecessary referrals.16,21,22 When used appropriately, CDRs can reduce 
overcrowding in EDs, improve access to EDs and decrease patient mortality.11,23 CDRs have a 
high level of acceptability among most physicians,24 and have been shown to increase efficacy 
and decrease cost.25  
 
However, adherence to well-established rules is at times inconsistent, leading to a negative 
impact both on healthcare expenditure and patient care.19,26 Non-adherence is a common 
problem. Mahler et al.19 evaluated adherence to the HEART pathway for assessment of chest 
pain. They found that non-adherence occurred in 28 of 141 patients (20%), with under-testing 
occurring in 9 patients and over-testing in 19 patients. Although none of the 28 patients suffered 
a major adverse cardiac event at 30 days, the net effect of non-adherence was 10 additional 
hospital admissions among patients identified as low-risk and appropriate for early discharge. 
The decreased discharge rate of 7% is clinically significant; with an estimated 500,000 chest 
pain presentations to Australian EDs,2 a 7% reduction in discharges would result in 35,000 
avoidable hospitalisations per annum. 
 
Inconsistent adherence to accelerated pathways was also observed in a study26 comparing the 
novel Emergency Department Assessment of Chest Pain Score accelerated diagnostic pathway 
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(EDACS-ADP) to a controlled accelerated diagnostic pathway (ADAPT-ADP). None of the 
patients in the low risk groups in either arm had a major adverse event within 30 days. The 
EDACS-ADP identified 11.8% more low-risk patients than ADAPT-ADP. Despite this, the 
discharge rate between the two arms was not significantly different, suggesting non-adherence 
to the protocols. 
 
Barriers to adherence of CDRs include physician disagreement with the rules, physicians’ view 
that the rules are over-simplifications or too time-consuming to apply, patients’ insistence on 
an investigation or intervention, and misinterpretation of the rules.21,25,27 Recommendations on 
how to improve CDRs utilisation include continuing education to maintain and improve 
practice performance,28 and use of clinical decision support systems to ensure the use of 
CDRs.29 
 
When appraising the short- and long-term utilisation of the IMPACT protocol within the ED 
setting, the protocol should be evaluated in the context of translational research. Translational 
research is a complex, multi-stage process of applying research findings to improve clinical 
practice or promote health benefits.30,31 There had been increasing interest in the field of 
translational research, with one of the most significant motivations arising from the protracted 
period of time it took to transform basic scientific ideas into clinical practice and health 
impacts.32 The translation of major findings to clinical applications is often sluggish and 
inefficient.33 Morris et al.15 evaluated the literature on translational research and found that it 
required an average of seventeen years for research evidence to reach clinical practice. In 
addition, only 14% of original research turned into interventions of benefit to patient care.34 
Contopoulos-Ioannidis et al.35 examined 101 articles in six major science journals that studied 
technology with promising therapeutic or preventative uses, and found that the median 
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translation lag was twenty-four years between first description and earliest highly cited article. 
Only five new technologies had been licensed for clinical use and only one was used 
extensively for the licensed indications. It required an average of nine years for interventions 
to be implemented even after they were recommended as evidence-based practice in systematic 
reviews and guidelines.34 
 
To improve the success of translational research, which is determined by minimising time 
while preserving quality and cost to maximise the returns from research,31 many studies had 
looked to identifying “time lags” that caused delay in research results being translated into 
clinical interventions.36,37 Green et al.34 suggested that long periods of delay were partially due 
to the process of how research became clinical practice, with multiple stages such as 
acceptance, publication, indexing, and inclusion in systematic reviews.  
 
In addition, treatment effectiveness may not convey implementation effectiveness, which relies 
on the interplay of acceptability, adoption, appropriateness, costs, feasibility, fidelity, 
penetration and sustainability.38 The majority of research included in systematic reviews with 
influence in recommending evidence-based practices had been conducted in highly controlled 
environments. This maximised internal validity but restricted external validity. Acceptability 
(the perception among stakeholders that a given innovation is agreeable), appropriateness (the 
perceived fit, relevance or compatibility of the innovation for a given setting, provider or 
consumer) and feasibility (the extent to which the new innovation can be successfully used 
within a given setting) may hence be limited.34,38 Sustainability, the extent to which a newly 
implemented innovation is maintained within a service setting’s ongoing operations, is also 
difficult to ascertain within clinical trials, but greatly influences the success of translating 
research findings into clinical practice.38 Basic research has led to many notable advances, but 
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there are a multitude of hurdles between promising findings and successful implementation of 
those results in a clinical setting. Consequently, there has been a trend towards increasing the 
focus on applied clinical research, which had been demonstrated to have greater immediate 
health, social and economic effects than basic research.37 To maximise the applicability of 
research, studies should be informed by burden of disease, with a focus on answering relevant 
and important questions in areas of need and minimising time lags.34,37 
 
Implementation effectiveness of an accelerated diagnostic pathway, the ADAPT-ADP, was 
evaluated in the Accelerated Chest pain Risk Evaluation (ACRE) Project.39 The 
implementation of the ADAPT-ADP was found to be associated with a reduction in ED length 
of stay, total hospital length of stay and the need for hospital admission. The implementation 
was accomplished across a variety of hospital types including metropolitan centres and regional 
hospitals. Of note, the implementation had been achieved within four years of publication of 
the original evidence, a shorter time frame than the average of seventeen years as reported by 
Morris et al.15 A range of factors had been identified by stakeholders to have contributed to the 
successful implementation of the ADAPT-ADP.40 Acceptability was achieved through the 
stakeholders’ knowledge and awareness of the accelerated diagnostic pathway, its supporting 
evidence and how the pathway was used in practice. Adoption was aided by the ADAPT-ADP 
being an adaptation, rather than replacement, of pathways and guidelines in current use, as well 
as being simple to use and the belief by stakeholders that it was easily accessible. It was 
interesting to note that although fidelity (the degree to which an intervention was implemented 
as prescribed by the original protocol) was suggested to be a component of a successful 
implementation by Procter et al.38, the ACRE authors attributed some success of the ADAPT-
ADP’s implementation to being able to be flexible in order to adapt to local processes.40 
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However, despite its successful implementation, ACRE identified areas of difficulties 
regarding the implementation process.40 The ADAPT-ADP was a pathway utilised in the ED, 
but required the engagement of various other specialties, such as cardiology and internal 
medicine. In addition, despite its ease of use, sustainability may prove to be difficult due to the 
high turnover of both senior and junior medical staff in the ED. Similar difficulties may prevent 
the successful use of the IMPACT protocol outside of a trial setting, despite promising results 
during its implementation stage.  
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Rationale 
The IMPACT protocol had been shown to be promising in its implementation phase as an 
accelerated protocol for the assessment of chest pain. It was found to be safe, with no adverse 
impact on health outcome.1 It was also cost and resource efficient, classifying a larger 
proportion of patients presenting to ED with chest pain as low-risk (18% with the IMPACT 
protocol (previously named Brisbane protocol) vs <1% with the 2006 NHFA/CSANZ 
guidelines) and thus decreasing the proportion of patients who require further investigations 
(55% vs 62%). Using the IMPACT protocol resulted in spending an average $1229 less than 
the traditional approach per patient, saved an average of twenty-six hours in hospital per 
patient, and allowed for a higher discharge rate of low- and intermediate-risk patients from ED 
within four hours (72% vs 51%).14 Despite the desirable outcomes achieved by the IMPACT 
protocol during its trial period, the IMPACT protocol required evaluation in its post-
implementation stage. 
 
Specific aims 
In this study, we sought to provide an initial investigation into the implementation effectiveness 
of the IMPACT protocol. The IMPACT protocol included zero- and two-hour troponin testing 
for all low- and intermediate-risk patients. Thus, this study investigated troponin ordering 
practices of clinicians in the post-implementation period. The proportion of patients 
undergoing zero- and two-hour testing was examined and compared to that reported by the 
IMPACT study.1 We also reported ED and SSU length of stay and proportion of patients 
admitted in the post-implementation period.  
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Methods 
Study Design 
This was an observational study of adult patients presenting to the ED of the RBWH, a large 
tertiary hospital in Australia, between April 2014 and June 2016. This study period commenced 
immediately after the trial period of the IMPACT protocol. The IMPACT protocol was 
implemented as the standard chest pain assessment protocol at the RBWH ED for use at all 
hours (during and out of working hours) via several approaches, including formal and informal 
education sessions, and large posters on display.  
 
Participants  
The study included adult patients who had a minimum of two troponins ordered within 24 
hours, with at least one troponin ordered within four hours of presentation to the ED. Patients 
with only one troponin were excluded, as the ordering of a single troponin test suggested that 
the patient was not being investigated for ACS.  
 
Measurements 
Patients met the criteria for hospital admission if they were admitted to an inpatient unit from 
either the ED or SSU. Intention to undergo an accelerated chest pain assessment process was 
defined as having a non-elevated troponin test on presentation (zero hours) and at two hours. 
Intention to undergo accelerated assessment was evaluated because patients were no longer 
being enrolled onto the study via a consent process. No clinical data directly indicated the 
classification of a patient’s risk group. Cardiac troponin testing is integral in the diagnosis of 
ACS, and a rise in serial troponin testing indicates acute myocardium damage. Thus, the 
inclusion of patients undergoing serial troponin testing soon after presentation to ED would 
identify the group of patients being investigated for ACS with a high degree of accuracy. In 
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addition, obtaining pathology testing data would be more reliable and accessible than 
determining the differential diagnoses being considered during a patient’s presentation. 
Troponin was measured using the Beckman Coulter AccutTnI+3 assay, with values exceeding 
0.040mg/L deemed to be elevated. 
 
It was recognised that within the clinical context, troponins may not be performed exactly 
within the recommended time period. Errors in the time entered on the database were also 
possible. As such, a presentation troponin (zero-hour troponin) was considered to be any 
troponin taken within 1.5 hours of presentation and a two-hour troponin was any troponin taken 
within four hours of presentation. Patients were also considered to have accelerated assessment 
if they had two troponins taken less than three hours apart within the first 4.5 hours after 
presentation. Data were analysed on an intention-to-treat basis. As such, patients meeting the 
criteria above were considered as part of the accelerated group even if they had further troponin 
testing or were admitted for other cardiac testing.   
 
Data Linkage 
Data was obtained from a number of hospital databases. Data on ED arrival and discharge time, 
patient demographics and discharge disposition were collected from the Emergency 
Department Information System (EDIS). Troponin results and the date and time that the 
troponin test was ordered were obtained from the state-wide pathology database (Auslab). 
Finally, hospital discharge time and diagnosis were obtained from the hospital based corporate 
information system (HBCIS). Deterministic linkage was used to link these three databases. 
This linkage method involved linking records based on exact agreement of selected match 
variables and was recommended where direct identifiers were available and were of good 
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quality. Each of the databases contained a unique patient record number (UR) and this was 
used in combination with date and time data to link the patient data. 
 
Statistical Analysis 
Data were analysed using Stata 14 (StataCorp, 2015, College Station, TX) and included 116 
weeks of data between 6th April 2014 and 25th June 2016. Descriptive statistics were calculated 
to define the baseline characteristics of the cohort. The proportion of patients in the overall 
cohort assessed using an accelerated strategy (zero- and two-hour troponin testing) was 
calculated along with median ED and SSU length of stay and the proportion of patients 
admitted. Such characteristics were also reported by presentation time (during or after work 
hours), to examine whether healthcare utilisation differed after hours when fewer resources are 
available (e.g. exercise stress testing). Working hours were defined as 0800 to 1700 hours on 
Monday to Friday. 
 
Regression analyses were conducted to examine the odds of having accelerated assessment, 
the odds of being admitted, and ED and SSU length of stay over the 116-week observation 
period. We sought to describe whether the outcomes changed across time and thus incorporated 
the number of weeks post-implementation as an independent variable. There was the possibility 
of non-independence within the data (e.g. patients presented multiple times). Thus, for the 
dichotomous outcomes (accelerated and hospital admitted), generalized estimating equations 
(GEE) were fit with an exchangeable working correlation and robust standard errors. A 
binomial error distribution and a logit link function were specified. For length of stay, the 
median length of stay was modelled using quantile regression with robust standard errors. 
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Regression models were fit in several steps. The first stage was examining the unadjusted 
relationship between each outcome and time. As the purpose of this analysis was to describe 
the data, rather than future prediction, we did not have a hypothesis about the nature of the 
relationship (i.e., linear, curvilinear). As such, restricted cubic splines were fit, enabling the 
relationship to be dictated by the data. Knots were set at May (the start of winter season in ED) 
and September (end of winter season in ED) each year. A sensitivity analysis was conducted 
with splines placed the 5th, 35th, 65th, and 95th percentile, as recommended by Harrell.41 This 
knot placement yielded similar results and so results were not reported here. 
 
The second stage included the regression of each outcome on time after adjustment for age and 
sex. This analysis was conducted to allow for adjustment of the regression equation to enable 
a comparison with the original IMPACT study. A non-linear association between age and each 
of the endpoints was postulated. This was because age was a key factor within the risk 
stratification system used for identifying patient risk and whether a patient can undergo 
accelerated care. To account for such non-linearity, restricted cubic splines were again fit. 
Knots were set at 30, 50, 65, and 85 years. These knots were chosen as they represented the 
5th, 35th, 65th, and 95th percentile, as recommended by Harrell.41   
30 
 
Results 
There were 11327 presentations in this study period (5239 during work hours and 6088 after 
hours) with one or more troponin tests taken within four hours of presentation to the ED. There 
were 3733 presentations with only one (non-elevated) troponin taking during the patient’s first 
twenty-four hours in hospital. These presentations were excluded from the current analysis as 
the ordering of a single troponin test suggested that the patient was not being investigated for 
ACS. This left 7594 presentations for analysis.  
 
Baseline characteristics of the cohort were shown in Table 1. Of this cohort, 15% of patients 
were discharged from the ED, with the remaining patients being admitted to the SSU or directly 
to the ward. An elevated troponin on presentation was present in 18% of the cohort. There were 
3805 patients with a presentation troponin <99th percentile who had a two-hour troponin; of 
these, 71 (1.87%) had a two-hour troponin >99th percentile. As with the IMPACT study, only 
patients with non-elevated zero- and two-hour troponins were considered accelerated; they 
remained in the accelerated group even if they had further troponin testing or were admitted 
for other cardiac testing.  This deemed 3734 patients as accelerated patients.  
 
Figure 2. Flow diagram of study participants 
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Table 1. Baseline characteristics of the study cohort 
 Post-IMPACT 
(n=7594) 
Mean Age (SD) 58.09 (17.1) 
Male Sex, n (%) 3185 (42.0%) 
Disposition from ED, n (%)  
     Admitted to ward 3654 (48.1%) 
     Admitted to short stay 2715 (35.8%) 
     Discharged Home 1119 (14.7%) 
     Left against medical advice 59 (0.8%) 
     Inter-hospital transfer (IHT) 39 (0.5%) 
     Died in the ED 8 (0.1%) 
Median (IQR) time to zero-hour troponin, hours 0.5 (0.3-0.8) 
Median (IQR) time from arrival to second troponin for 
accelerated patients, hours 
2.7 (2.4-3.2) 
Median (IQR) time to six-hour troponin in non-accelerated 
patients, hours 
7.0 (6.3-8.6) 
Presented after work hours, n (%) 4120 (54.3%) 
Troponin >99th percentile on presentation, n (%) 1380 (18.2%) 
 
Data on healthcare utilisation is provided in Table 2. The median hospital length of stay for the 
overall cohort was just less than one day. Patients intended for an accelerated protocol had a 
shorter hospital length of stay, particularly when presenting during working hours. One quarter 
of patients intended for an accelerated chest pain protocol were admitted to hospital. These 
patients were admitted to specialised cardiac units (26.5%) or general medical units (73.5%). 
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Table 2. Health care utilisation by presentation time 
  Overall 
Cohort 
(n=7,594) 
During 
working 
hours 
(n=3,474) 
Outside of 
working 
hours 
(n=4,120) 
Difference 
during versus 
outside of 
working hours 
(95% CI) 
Median (IQR) Hospital 
length of stay for all 
patients, hours 
23.9 
(7.9-75.7) 
24.8 
(7.1-74.4) 
21.9 
(9.1-78.6) 
-2.9 
(-4.9 to -0.8) 
Hospital admission n (%) 4,066 
(53.5%) 
1863 
(53.6%) 
2203 
(53.5%) 
-0.2% 
(-2.4 to 2.1%) 
Patients accelerated, n (%) 3734 
(49.2%) 
1797 
(51.7%) 
1937 
(47.0%) 
-4.7% 
(-7.0 to -2.4%) 
Accelerated patients 
admitted, n (%) 
876 
(23.3%) 
419 
(23.3%) 
457 
(23.6%) 
0.3% 
(-2.5 to 3.0%) 
Median (IQR) hospital 
length of stay for 
accelerated patients, hours 
9.8 
(4.9-22.7) 
8.0 
(5.0-24.0) 
11.6 
(4.8-20.9) 
3.5 
(1.6 to 5.5) 
Median (IQR) ED and 
SSU length of stay for 
accelerated patients, hours 
7.2 
(4.7-14.8) 
6.7 
(4.7-16.6) 
8.1 
(4.6-14.7) 
1.4 
(0.8 to 1.9) 
CI = confidence interval, IQR = interquartile range; 95% CI calculated using clustered robust 
standard errors to account for patients presenting multiple times.  
Hospital length of stay includes ED and SSU length of stay  
 
Figure 3 provides the predicted proportion of accelerated patients each week following 
regression of accelerated care over time. The original IMPACT study reported that 75.6% of 
patients were placed on an accelerated protocol.1 There was an association between weeks after 
implementation (entered as cubic splines) and the proportion of patients accelerated (χ2=76.2, 
p <0.001).  Specifically, the proportion of patients deemed suitable for accelerated assessment 
increased rapidly over the first six months after implementation of the IMPACT protocol. 
Accelerated assessment then slowly increased for a further year, before plateauing to an 
expected 53.7% (95% CI: 49.6-57.8%) by the end of the study period (Figure 3). 
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Figure 3. Percentage of patients intended for accelerated assessment by time. The black line 
represents the predicted proportion of patients undergoing accelerated assessment across time. 
The blue line represents actual percentages accelerated by week.  
 
 
A second regression examined the odds of being accelerated following adjustment for age and 
sex. The odds of being accelerated were 25% lower for males compared to females (OR=0.75, 
95% CI: 0.67-0.84) and decreased with increasing age (Supplementary Figure 1). Figure 4 
provides the probability of being accelerated by week at an average age of 51 years (the average 
age of the original IMPACT cohort). This figure shows that, after adjustment for age, the 
expected proportion of accelerated patients was 66.7% (95% CI: 61.8-71.4%) for males and 
72.7% (95% CI: 68.2-76.9%) for females by the end of the study period.  
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Figure 4. Percentage of patients intended for accelerated assessment adjusted for age and sex. 
Data are plotted for an average age of 51 years. The blue and purple lines represent the 
predicted proportion of female and male patients respectively undergoing accelerated 
assessment across time. 
 
For the overall cohort, regression of the proportion of patients admitted to hospital on weeks 
after implementation (as cubic splines) indicated that hospital admission changed across time 
(χ2=10.3, p=0.04).  Hospital admission slightly decreased over the first six months post 
implementation of IMPACT and then plateaued over the remaining period (Figure 5). The 
expected proportion of patient admitted to hospital by the end of the observation period was 
50.4% (95% CI: 46.4-54.4%).  
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Figure 5. Proportion of patients admitted to hospital by time 
 
A second regression was conducted examining the odds of being admitted for accelerated 
patients only, including adjustment for age and sex. The odds of being admitted were similar 
for males and females (Male OR=1.1, 95% CI: 0.96-1.3) and increased with increasing age 
(Supplementary Figure 2). Weeks after implementation was not associated with admission 
rates (χ2=7.9, p=0.09), indicating that the proportion of accelerated patients admitted did not 
change across this study period.  Figure 6 provides the probability of being admitted by week 
at an average age of 51 years (the average age of the original IMPACT cohort). The expected 
proportion of patients admitted to hospital at the end of the study period was 19.1% (95% CI: 
14.9-24.1%) for females and 21.1% (95% CI; 16.5-26.5%) for males. 
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Figure 6. Adjusted probability to being admitted to hospital for accelerated patients. Data 
presented for an average age of 51 years. 
 
ED and SSU length of stay changed across time (F=3.29, p =0.01). There was a slight decrease 
in ED and SSU length of stay for the first year after the introduction of IMPACT, but length 
of stay increased again during the second year (Figure 7).  For accelerated patients, after 
adjusting for age and sex, the time after implementation did not have a clear association with 
ED and SSU length of stay (F=2.3, p=0.06).  At the end of the study period, predicted median 
ED and SSU length of stays for accelerated patients was 8.7 hours (95% CI: 8.0-9.4) for males 
and 8.4 hours (95% CI: 7.7-9.1 hours) for females (Figure 8). Length of stay did not differ by 
sex (median difference=-0.35, 95% CI: -0.72 to 0.02) but increasing age was associated with 
increasing length of stay (Supplementary Figure 3).  
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Figure 7. Median ED and SSU length of stay by time 
 
Figure 8. ED and SSU length of stay by time for accelerated patients. Data presented for an 
average age of 51 years.  
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Discussion 
This evaluation of the implementation of the IMPACT protocol demonstrated that after the 
conclusion of the original IMPACT study period, there was uptake of the IMPACT protocol in 
a clinical setting. There was an initial increase in proportion of patients being accelerated before 
plateauing before the end of the study period. The secondary outcomes of ED and SSU length 
of stay and admission rates for accelerated patients remained unchanged throughout this study 
period, suggesting consistency in the use of the IMPACT protocol at the RBWH ED. 
 
The overall proportion of patients who underwent accelerated assessment during this study 
period was 49.2%, lower than the 75.6% reported by the IMPACT study. A lower proportion 
was expected in a transition from a research setting, where dedicated research nurses facilitated 
the use of the IMPACT protocol, to real world conditions. It was also partially attributed to the 
nature of the original IMPACT study where some high-risk patients may not have been 
recruited. For example, if a patient was too unwell or was unable to consent, the patient may 
not be able to be enrolled in the IMPACT study. In this observational study, patients were not 
required to be enrolled and were automatically included based on the troponin testing inclusion 
criteria, hence there may be a higher capture rate of high-risk patients, leading to the proportion 
of accelerated patients to appear lower when compared to the IMPACT study.  
 
As this study’s cohort was older than that of the IMPACT study’s (58 years in this study vs 51 
years in the IMPACT study), the proportion of patients being accelerated was adjusted for sex 
and age (to the average age of 51 years) to allow for comparison between the two studies and 
evaluate the IMPACT protocol’s uptake. After adjustment, the predicted proportion of patients 
being accelerated reached 66.7% for males and 72.7% for females by the end of the study 
period. The proportion of patients being accelerated increased over this study period, 
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suggesting increasing acceptance of the IMPACT protocol over time. The proportion of 
patients accelerated were achieved due to multiple factors. Firstly, the protocol had been 
implemented in a trial at the RBWH ED for a period of time prior to this study, with research 
staff previously ensuring that troponin ordering practices were in accordance with the IMPACT 
protocol. There was consistent leadership engagement to ensure correct use of the protocol. 
Secondly, the IMPACT protocol was resource efficient and thus clinicians were likely inclined 
to use it. The IMPACT protocol has previously been shown in a study by Cullen et al. to allow 
accelerated patients to be discharged earlier while maintaining safety;1 the median hospital 
length of stay for accelerated patients was 9.8 hours, shorter than the median hospital length of 
stay of 23.9 hours for all patients. Taking into account that the latter group included high risk 
patients, the shorter hospital length of stay in the accelerated group may have been contributed 
to not only by the second troponin test being ordered earlier, but also potentially by allowing 
further investigations to be performed on the same day during working hours (for example, 
exercise stress test). This was consistent with the median hospital length of stay for accelerated 
patients being shorter if they presented during working hours (8.0 hours) than if presenting 
outside of working hours (11.6 hours). Likewise, the median ED and SSU length of stay for 
accelerated patients increased from 6.7 hours during working hours to 8.1 hours outside of 
working hours.  
 
The median ED and SSU length of stay was 7.2 hours for accelerated patients. The SSU is an 
area within the ED that is separate from the ED acute assessment area, and is designated for 
short term observations, treatment, assessment and reassessment of patients. It is designed for 
short term stays no longer than 24 hours. The median ED and SSU length of stay for accelerated 
patients did not change across this study period, indicating that the accelerated assessment 
using the IMPACT protocol persisted throughout this post-implementation period.  
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The median hospital length of stay for accelerated patients in this study was 9.8 hours, while 
the IMPACT study’s median hospital length of stay was 5.1 hours for low risk patients and 7.7 
hours for intermediate risk patients. The longer length of stay in this study was attributed to the 
transition from a research setting, where dedicated research nurses ensured patient flow, to real 
world conditions. In addition, the IMPACT study included only presentations during working 
hours, whereas this study included presentations at all hours, potentially contributing to a 
longer length of stay as some services were only available during working hours (for example, 
exercise stress tests).  
 
The hospital admission rate for the overall cohort decreased over the first six months post-
implementation, in line with the proportion of accelerated patients increasing over the same 
period, suggesting gradual increasing uptake of the IMPACT protocol. The hospital admission 
rate for accelerated patients remained unchanged across this study period, indicating 
sustainability in the use of the IMPACT protocol and its consistent effect on this secondary 
outcome. Adjusted for age and sex, the accelerated cohort’s admission rate was 19.1% for 
females and 21.1% for males, comparable to the 17% admission rate for low- and intermediate-
risk patients in the IMPACT study.  
 
Increased age was associated with decreased odds of being accelerated and increased admission 
rates. This was likely due to age (over 40 years old) being an exclusion criterion for the low 
risk group, and increasing age being associated with multiple co-morbidities that would place 
the patient in the high-risk group. ED and SSU length of stay increased with age but decreased 
after the age of 60, possibly reflective of the decision to admit older patients at an earlier stage 
of their assessment.  
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Given that the proportion of accelerated patients plateaued by the end of this study period, 
along with the secondary outcomes of ED and SSU length of stay and admission rates for 
accelerated patients, the IMPACT protocol was shown to be sustainable under real world 
conditions. 
 
Limitations 
This study was conducted at the single centre that was responsible for the development of the 
IMPACT protocol that was used in this study. The clinicians were exposed to the IMPACT 
protocol during the original trial period. This likely increased acceptability, and thus eased its 
adaptation as the standard protocol during the post-implementation period. To assess 
generalisability, further study would need to be performed to ascertain whether translation 
would be similarly successful in other centres that were not involved with the development of 
the IMPACT protocol.  
 
In addition, this observation period immediately succeeded the trial period; while data was 
available in the period prior to the implementation of IMPACT protocol as standard care, the 
data would be reflective of that during the trial period. Therefore, no data prior to the utilisation 
of the IMPACT protocol was available for comparison. 
 
Patients were included based on troponin testing being performed. At RBWH, samples for 
troponin testing were routinely taken on presentation for chest pain suspected of ACS. Raised 
cardiac troponin indicated damage to the myocardium and was therefore specifically used in 
the assessment of cardiac complaints. Also, troponin measurement was a core component of 
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the guidelines for the management of ACS. As such, we believed that including patients based 
on the presence of troponin testing would identify the group of patients being investigated for 
ACS with a high degree of accuracy. While this method may miss patients, we believed this 
was likely to be a small number as troponin testing would be required for the diagnosis of ACS. 
Inclusion based on troponin testing also created inclusion bias as the primary outcome of this 
study was the proportion of patients receiving zero- and two-hour troponin testing. However, 
alternative methods of identifying patients from the databases, such as using a presenting 
complaint or discharge diagnosis, were likely to be less sensitive and specific than troponin 
testing given the length of time required to assign an accurate diagnosis and that ACS could 
have a broad range of potential presentations.  
 
Patients were excluded if they only had a single troponin test performed. The guideline used 
for comparison to the IMPACT study and hence this study was the 2006 NHFA/CSANZ 
guideline, which recommended that “a repeat serum troponin measurement (unless already 
positive) should be performed at least eight hours after the last episode of pain or other 
symptoms of coronary insufficiency”.9 We acknowledge that a single troponin test may be used 
at a clinician’s discretion in the investigation of ACS, and hence the exclusion of patients with 
only one troponin test performed may miss cases of chest pain being investigated for possible 
ACS; however, given that at the time of the study, there were no firm recommendations on 
when a single troponin should be used, it would not be possible to determine which of the 
patients receiving a single troponin test were being investigated for ACS.  
 
It was difficult to assess the degree of fidelity achieved. It had been assumed that the ordering 
of a zero-hour troponin test followed by a two-hour troponin test equated to the patient being 
stratified onto the accelerated pathway. However, as clinicians ordered investigations at their 
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own discretion, the ordering of troponin testing may not correspond to the timing that had been 
recommended by the IMPACT protocol. For example, the age-adjusted figures of 66.7% of 
females and 72.7% of males being accelerated may be deceptively high if patients with high-
risk characteristics received zero- and two-hour troponins. On the other hand, accelerated 
patients may be incorrectly grouped into the high-risk group if their second troponin test was 
delayed due to workflow issues (for example, no available staff to take the blood sample for 
troponin testing at two hours). However, given the number of patients included in this study, it 
was likely that any effect caused by discrepancy in troponin ordering would be insignificant.  
 
The IMPACT protocol utilised the high-risk criteria from the 2006 NHFA/CSANZ guidelines,9 
which were current at the time of the study. Updated guidelines were released in 2016, with 
minor changes to the high-risk group.2 However, these changes were unlikely to have caused 
significant changes to the results, especially in the comparison between the IMPACT trial 
period and post-implementation period as both utilised the 2006 guidelines. 
 
Conclusion 
This study demonstrated that the IMPACT protocol was being adopted and utilised in a clinical 
setting following conclusion of the original trial. The initial increase in proportion of patients 
being accelerated, followed by a plateau before the end of the study period, indicated 
acceptability, adoption and sustainability of the IMPACT protocol. The secondary outcomes 
of ED and SSU length of stay and admission rates remained unchanged for accelerated patients 
across the post-implementation period, demonstrating sustainability and consistency in the use 
of the IMPACT protocol at the RBWH ED.  
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Supplementary Appendix 
Supplementary Table 1: Comparison of risk stratification criteria from the 2006 National Heart 
Foundation of Australia/Cardiac Society of Australia and New Zealand (NHFA/CSANZ) 
guideline and IMPACT protocol 
 
2006 NHFA/CSANZ guidelines  IMPACT protocol  
High risk  
Presentation with clinical features consistent with ACS and any of 
the following: 
• Repetitive or prolonged (>10 min) chest pain or discomfort 
• Elevation of at least one cardiac biomarker (troponin or CK-
MB) 
• Persistent or dynamic ST-segment depression ≥0.5mm, or 
new T-wave inversion ≥2mm 
• Transient ST-segment elevation (≥0.5mm) in more than two 
contiguous leads 
• Haemodynamic compromise – systolic blood pressure 
<90mmHg, cool peripheries, diaphoresis, Kilip class >1, 
and/or new onset mitral regurgitation 
• Sustained ventricular tachycardia  
• Syncope  
• Left ventricular systolic dysfunction (LVEF fraction <40%) 
• Prior percutaneous coronary intervention within six months 
or prior coronary artery bypass surgery 
• Diabetes (with typical symptoms of ACS) 
• Chronic kidney disease, eGFR <60mL/min/1.73m2 (with 
typical symptoms of ACS) 
 
Same as 2006 NHFA/CSANZ guidelines 
Intermediate risk   
Presentation with clinical features consistent with ACS, with no 
high risk features, and any of: 
• Chest pain or discomfort within the past 48 hours that 
occurred at rest, or was repetitive or prolonged (but 
currently resolved) 
• Age >65 years 
• Known coronary heart disease – prior myocardial infarction 
with LVEF ≥40%, or known coronary lesion more than 50% 
stenosed 
• No high-risk changes on ECG (as listed above) 
• Two or more of the following risk factors: known 
hypertension, family history, active smoking or 
hyperlipidaemia 
• Presence of known diabetes (with atypical symptoms of ACS) 
• Chronic kidney disease, eGFR <60 mL/min/1.73m2 (with 
atypical symptoms of ACS) 
• Prior aspirin use 
 
No high risk features, and any of 
• Age ≥40 years 
• Chronic kidney disease, eGFR <60mL/min/1.73m2 (with 
atypical symptoms of ACS) 
• Diabetes (with atypical symptoms of ACS) 
 
Low risk   
Presentation with clinical features consistent with an ACS with no 
intermediate or high risk features 
 
No intermediate or high risk features, and 
• No history of diabetes  
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Supplementary Figure 1. Proportion of patients accelerated by age  
 
 
Supplementary Figure 2. Proportion of patients admitted by age 
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Supplementary Figure 3. ED and SSU length of stay by age  
 
 
